Patent ID: 11890492
Assignee: SOUND WAVE INNOVATION CO., LTD.
Field: Medical technology (Instruments)
Classification: CPC A | IPC A

Claim 4:
5. A program stored in a device for treating dementia, the device including:
a plurality of ultrasound probes;
an ultrasound transducer arranged in each of the ultrasound probes and configured to propagate unfocused ultrasound energy to an entirety of a brain; and
an ultrasound generator connected to each of the ultrasound probes,
the program being configured to cause the device to execute a function of causing the ultrasound transducer arranged in each of the ultrasound probes to generate unfocused ultrasound energy through control by the ultrasound generator,
wherein the ultrasound generator is configured to control the ultrasound transducer so as to sequentially radiate the unfocused ultrasound energy between the plurality of ultrasound probes,
wherein a frequency of the radiated unfocused ultrasound energy is set within a range of from 0.5 MHz to 0.8 MHz,
wherein the radiated unfocused ultrasound energy is a non-continuous wave, and a number of cycles thereof is set within a range of from 1 cycle to 64 cycles,
wherein the unfocused ultrasound energy irradiation from the plurality of ultrasound probes is performed at an interval of 0.30/f ms or more, where f represents a frequency (MHz) of a pulse to be transmitted,
wherein a sound pressure of radiated ultrasound directly under the ultrasound transducer is within a range of from 0.1 MPa to 1.5 MPa,
wherein a treatment time with ultrasound is set within a range of 15 to 60 minutes,
wherein the dementia is treated by enhancing expression of endothelial nitric oxide synthase (“eNOS”),
wherein the unfocused ultrasound energy is diffused in an inversely tapered shape gradually enlarging in diameter toward a radiation direction, and
wherein a spreading angle of an inclined surface of the unfocused ultrasound energy in the inversely tapered shape enlarging in diameter is from 50° to 100°, and
improving cognitive function by stimulating vascular endothelial cells by applying an average intensity of 720 mW/cm2 or less to enhance the expression of eNOS, VEGF, and bFGF.